CYCN THERNPV Stock

CYCN

US23255M2044

Market Closed - Nasdaq 16:00:00 2026-11-13 EST			5-day change	1st Jan Change
31.65 ^USD	+1.18%		+1.93%	+256.02%

09-07	Cyclerion Therapeutics, Inc.(NasdaqCM:CYCN) dropped from NASDAQ Composite Index	CI
09-07	Korsana Biosciences, Inc. completed the acquisition of Cyclerion Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI

Last Transcript: CYCN THERNPV

Cyclerion Therapeutics, Inc., Korsana Biosciences, Inc. - M&A Call

04-01

More transcripts

Analysts' recommendations: CYCN THERNPV

21-10-20	Cyclerion Therapeutics : Truist Securities Starts Cyclerion Therapeutics at Buy with $14 Price Target	MT
21-09-27	Cyclerion Therapeutics : Cantor Fitzgerald Starts Cyclerion Therapeutics at Overweight with $7 Price Target	MT
21-09-24	Cyclerion Therapeutics : Cantor Fitzgerald Initiates Cyclerion Therapeutics at Overweight Rating With $7 Price Target	MT

More recommendations

News in other languages: CYCN THERNPV

25-09-24

USA-Les valeurs à suivre à Wall Street (actualisé)

More news

Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
26-11-13	US$31.65	+1.18%	225,511
26-11-12	US$31.28	-1.76%	167,583
26-11-11	US$31.84	+2.35%	167,280
26-11-10	US$31.11	-0.19%	383,991
26-11-09	US$31.17	+0.39%	159,942

Delayed Quote Nasdaq

More quotes

Market Cap	15.48M 14.03M 12.98M 11.71M 22.06M 1.46B 22.84M 156M 61.81M 780M 58.09M 56.86M 2.48B	P/E 2024	-2.65x	P/E 2025	-1.15x
Enterprise Value	12.24M 11.09M 10.26M 9.26M 17.44M 1.15B 18.06M 123M 48.87M 617M 45.94M 44.96M 1.96B	EV / Sales 2024	2.46x	EV / Sales 2025	0.77x
Free-Float	-	Yield 2024 *	-	Yield 2025	-

09-07	Cyclerion Therapeutics, Inc.(NasdaqCM:CYCN) dropped from NASDAQ Composite Index	CI
09-07	Korsana Biosciences, Inc. completed the acquisition of Cyclerion Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI
08-04	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-14	Cyclerion Therapeutics, Inc. announced that it has received $200 million in funding	CI
05-12	Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-06	Top Premarket Decliners	MT
04-01	Top Midday Gainers	MT
04-01	Cyclerion Therapeutics, Inc., Korsana Biosciences, Inc. - M&A Call
04-01	Cyclerion Therapeutics and Korsana Biosciences announce merger agreement	RE
03-31	Korsana Biosciences, Inc. entered into a definitive merger agreement to acquire Cyclerion Therapeutics, Inc. from a group of shareholders for approximately $270 million in a reverse merger transaction.	CI
03-31	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Cyclerion Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-17	Cyclerion Therapeutics announces progress toward Cyc-126 phase 2 proof-of-concept study with FDA feedback	RE

08-04	Cyclerion Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
04-01	Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement	BU
02-17	Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board	AQ
01-05	Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression	AQ
11-12	Cyclerion Therapeutics : Amendment to Annual Report (Form 10-K/A)	PU

1 day	+1.18%
Current month	+34.57%
3 months	+19.30%
6 months	+46.32%
Current year	+256.02%

Current year	7.19	59.36
1 year	7.19	59.36
3 years	7.19	66.29
5 years	7.19	413
10 years	7.19	3,199

CYCN THERNPV Stock

Stocks

CYCN

US23255M2044

Valuation: CYCN THERNPV

Chart: CYCN THERNPV

Latest news: CYCN THERNPV

Last Transcript: CYCN THERNPV

Analysts' recommendations: CYCN THERNPV

Press Releases: CYCN THERNPV

News in other languages: CYCN THERNPV

Quotes and Performance

Price Extremes

Latest insider transactions

Financials

Company Profile

Quotes

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/16/26	Peter Hecht	Conversion	Director	351,037	8.1065%
7/16/26	Peter Hecht	Conversion	Director	-351,037	100.0000%
8/7/25	Rhonda Chicko	Free	Chief Financial Officer	25,000	0.9225%

	2024	2025
Net sales	2M 1.81M 1.68M 1.51M 2.85M 189M 2.95M 20.14M 7.98M 101M 7.51M 7.35M 320M	2.07M 1.88M 1.74M 1.57M 2.96M 196M 3.06M 20.88M 8.28M 104M 7.78M 7.62M 332M
Net income	-3.06M -2.77M -2.56M -2.31M -4.36M -288M -4.51M -30.78M -12.21M -154M -11.47M -11.23M -489M	-3.53M -3.2M -2.96M -2.67M -5.03M -333M -5.21M -35.52M -14.09M -178M -13.24M -12.96M -564M
Net Debt	-3.23M -2.93M -2.71M -2.44M -4.61M -305M -4.77M -32.54M -12.9M -163M -12.13M -11.87M -517M	-3.24M -2.94M -2.72M -2.45M -4.62M -305M -4.78M -32.62M -12.94M -163M -12.16M -11.9M -518M